Treatment Satisfaction in Multiple Sclerosis

Glanz, Bonnie I.; Musallam, Alexander; Rintell, David; Chitnis, Tanuja; Weiner, Howard L.; Healy, Brian C.

doi:10.7224/1537-2073.2013-021

Cited by 31 publications

(35 citation statements)

References 25 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…These results are supported by a previous study comparing patient satisfaction with natalizumab, glatiramer acetate, and interferons, which identified a trend toward greater satisfaction with the effectiveness of natalizumab than with the effectiveness of the other therapies. Furthermore, patients reported significantly greater satisfaction with the convenience of natalizumab treatment than with that of other therapies considered 24. Although natalizumab treatment requires monthly visits to an infusion center, patients reported satisfaction with the convenience of natalizumab in both the previous24 and current studies.…”

Section: Discussionmentioning

confidence: 71%

“…Furthermore, patients reported significantly greater satisfaction with the convenience of natalizumab treatment than with that of other therapies considered 24. Although natalizumab treatment requires monthly visits to an infusion center, patients reported satisfaction with the convenience of natalizumab in both the previous24 and current studies.…”

Section: Discussionmentioning

confidence: 71%

See 1 more Smart Citation

Long-term natalizumab treatment is associated with sustained improvements in quality of life in patients with multiple sclerosis

Foley¹,

Nair²,

Vollmer³

et al. 2017

PPA

View full text Add to dashboard Cite

BackgroundMultiple sclerosis (MS) patients experience lower health-related quality of life (HRQoL) than the general population. In clinical trials, natalizumab significantly improved HRQoL and reduced relapse rates and disability progression in patients with relapsing MS. In a 1-year analysis of patients included in the current study, HRQoL improvement occurred within 3 months of natalizumab initiation and continued for 1 year thereafter. However, natalizumab’s long-term efficacy in improving HRQoL has not been studied.MethodsIn this longitudinal, observational, single-arm US study, HRQoL and treatment satisfaction were evaluated in MS patients receiving intravenous natalizumab 300 mg every 4 weeks in clinical settings. Patients completed surveys at baseline and every 6 months for 3 years and reported the following measures: Short Form-12 Version 2 (SF-12v2), Multiple Sclerosis Impact Scale (MSIS-29), and Treatment Satisfaction Questionnaire for Medication.ResultsIn this study, 120 patients completed ≥3 years of natalizumab treatment. Significant HRQoL improvements were evident from baseline to year 3 by increases in SF-12v2 Physical Component Summary (PCS) and Mental Component Summary scores (P<0.01) and decreases in MSIS-29 physical and psychological scores (P<0.0001). Patients with less physical disability (baseline Disease Steps [DS] 0–2) had significant improvement from baseline to year 3 in SF-12v2 PCS (P<0.05) and MSIS-29 physical scores (P<0.05). Physical HRQoL outcomes in patients with baseline DS 3–6 remained stable over 3 years. Treatment satisfaction increased significantly from baseline to year 1 (P<0.0001) and was maintained in the following 2 years.ConclusionPatients reported physical and psychological HRQoL improvements over 3 years of natalizumab treatment, supporting the long-term efficacy of natalizumab in real-world settings. Lower baseline disease activity and earlier treatment were related to better outcomes, indicating the importance of starting natalizumab early in the disease course. Treatment satisfaction increased after natalizumab initiation and remained high over 3 years of treatment.

show abstract

Section: Discussionmentioning

confidence: 71%

Section: Discussionmentioning

confidence: 71%

Long-term natalizumab treatment is associated with sustained improvements in quality of life in patients with multiple sclerosis

Foley¹,

Nair²,

Vollmer³

et al. 2017

PPA

View full text Add to dashboard Cite

show abstract

“…People, however, perceive the efficacy benefits of different DMTs differently, and often this perception is the leading cause for stopping treatment [47][48][49]. It also seems that different DMTs provide different levels of satisfaction [50] which can be related to new drugs being perceived as better and the escalation strategy (transition from less risky to more risky treatments) implicitly portraying some drugs as more powerful than others.…”

Section: The Meaning Of Dmt Efficacy For People With Rrmsmentioning

confidence: 99%

Understanding treatment decisions from the perspective of people with relapsing remitting multiple Sclerosis: A critical interpretive synthesis

Eskytė

Manzano

Pepper

et al. 2019

Multiple Sclerosis and Related Disorders

View full text Add to dashboard Cite

“…The TSQM subscales have been found to explain 9% to 20% of the variance in adherence. 7 The original TSQM, vI, has been used with patients with MS 15,16 and has been found to be reliable, with Cronbach α values for subscales ranging from 0.79 to 0.93. 16 The TSQM vII was used in this study because it has equivalent measurement characteristics as the TSQM vI but uses four fewer items and more consistent wording.…”

Section: Independent Variablesmentioning

confidence: 99%

Associations Between Treatment Satisfaction, Medication Beliefs, and Adherence to Disease-Modifying Therapies in Patients with Multiple Sclerosis

Thach¹,

Brown²,

Herrera³

et al. 2018

International Journal of MS Care

View full text Add to dashboard Cite

Background: Adherence to disease-modifying therapy (DMT) remains problematic for many patients with multiple sclerosis (MS). An improved understanding of factors affecting DMT adherence may inform effective interventions. This study examined associations between treatment satisfaction, medication beliefs, and DMT adherence. Methods: A survey was mailed in 2016 to 600 adult patients with relapsing-remitting MS taking an injectable or oral DMT. Patients were sampled from the North American Research Committee on Multiple Sclerosis (NARCOMS) Registry. The survey measured self-reported DMT adherence (doses taken divided by doses prescribed during previous 2-week period—adherence ≥0.80), DMT satisfaction using the Treatment Satisfaction Questionnaire for Medication version II, medication beliefs using the Beliefs About Medicines Questionnaire, and demographic and clinical covariates. Relationships between variables were examined using multivariate logistic regression. Results: Final analyses included 489 usable surveys. Mean ± SD participant age was 60.5 ± 8.3 years. Most respondents were white (93.8%), female (86.6%), taking an injectable DMT (66.9%), and adherent to DMT (92.8%). Significant predictors of DMT adherence were age (odds ratio [OR], 1.086; 95% CI, 1.020–1.158; P = .011), type of DMT (oral vs. injectable; OR, 23.350; 95% CI, 2.254–241.892; P = .008), and DMT experience (naive vs. experienced; OR, 2.831; 95% CI, 1.018–7.878; P = .046). Conclusions: In patients with MS sampled from a patient registry, treatment satisfaction and medication beliefs were not significantly associated with DMT adherence. Based on significant predictors, younger patients, patients taking injectable DMTs, and patients with previous experience with another DMT(s) are at higher risk for nonadherence. Future research is warranted to assess relationships between variables in more diverse MS populations.

show abstract

Treatment Satisfaction in Multiple Sclerosis

Cited by 31 publications

References 25 publications

Long-term natalizumab treatment is associated with sustained improvements in quality of life in patients with multiple sclerosis

Long-term natalizumab treatment is associated with sustained improvements in quality of life in patients with multiple sclerosis

Understanding treatment decisions from the perspective of people with relapsing remitting multiple Sclerosis: A critical interpretive synthesis

Associations Between Treatment Satisfaction, Medication Beliefs, and Adherence to Disease-Modifying Therapies in Patients with Multiple Sclerosis

Contact Info

Product

Resources

About